Skip to main content
HeartCited

Chitosan High Triglycerides (Hypertriglyceridemia)

D 研究 予備的な研究(実験室研究、症例報告)のみが存在します。

Limited evidence for modest triglyceride reduction. Fat-binding mechanism may reduce dietary triglyceride absorption. Results are inconsistent across studies.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dchitosan\u0026condition\u003Dtriglycerides'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

結論

Limited evidence for modest triglyceride reduction. Fat-binding mechanism may reduce dietary triglyceride absorption. Results are inconsistent across studies.

Key Study Findings

Other
Therapeutic effects of alpha lipoic acid and/or caffeine-loaded chitosan nanoparticles on memory impairment and neurochemical …
Dose: None vs: None Outcome: Cognitive function 効果: None None

対象集団: Rat model

Other
Chitosan and solid lipid nanoparticles enhance the efficiency of alpha-lipoic acid against experimental neurotoxicity.
Dose: None vs: None Outcome: Oxidative stress, neuroinflammation, apoptosis 効果: None None

対象集団: AlCl3-induced neurotoxicity rat model

Key Statistics

3

研究数

200

参加者数

Positive

D

グレード

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

fatbinding:
1,500-3,000 mg/day before meals
cholesterolsupport:
1,000-3,000 mg/day

上限量: Not formally established; GI side effects at higher doses

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Positive --

推奨摂取タイミング: 15-30 minutes before meals containing dietary fat

Safety & Side Effects

報告されている副作用

  • Constipation
  • Gas and bloating
  • Nausea
  • Allergic reactions in those with shellfish allergy (contraindicated)

既知の相互作用

  • Fat-soluble vitamins (A, D, E, K — may reduce absorption)
  • Oral medications (may bind and reduce absorption — separate by 2 hours)
  • Warfarin (may reduce vitamin K absorption, affecting INR)

耐容上限摂取量: Not formally established; GI side effects at higher doses

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Chitosan help with High Triglycerides (Hypertriglyceridemia)?
Based on 3 studies with 200 participants, there is preliminary evidence that needs more research that Chitosan may support High Triglycerides (Hypertriglyceridemia) management. Our evidence grade is D (Very Early Research).
How much Chitosan should I take for High Triglycerides (Hypertriglyceridemia)?
Studies have used various dosages. A commonly studied range is 1,500-3,000 mg/day before meals. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Chitosan?
Reported side effects may include Constipation, Gas and bloating, Nausea, Allergic reactions in those with shellfish allergy (contraindicated). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Chitosan and High Triglycerides (Hypertriglyceridemia)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

に関する他の成分: High Triglycerides (Hypertriglyceridemia)

Chitosan 他の症状・状態について

References

  1. [1] Eman N Hosny et al.. Physiol Behav. 2024. Therapeutic effects of alpha lipoic acid and/or caffeine-loaded chitosan nanoparticles on memory impairment and neurochemical changes in high-fat diet-induced obese … doi:10.1016/j.physbeh.2024.114697 PubMed
  2. [2] Heba H Metwaly et al.. Toxicol Mech Methods. 2022. Chitosan and solid lipid nanoparticles enhance the efficiency of alpha-lipoic acid against experimental neurotoxicity. doi:10.1080/15376516.2021.1998275 PubMed
  3. [3] Norhayati Mohamed Noor et al.. Pharmaceutics. 2020. In Vitro Performance of Dutasteride-Nanostructured Lipid Carriers Coated with Lauric Acid-Chitosan Oligomer for Dermal Delivery. doi:10.3390/pharmaceutics12100994 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。